Please ensure Javascript is enabled for purposes of website accessibility

3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?

By Keith Speights – Updated Apr 20, 2019 at 5:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?

Big drug companies make big profits. But which are the most profitable of all?

There are 21 drug stocks in the S&P 500 index, representing the biggest drugmakers in the U.S. The three most profitable companies in this group based on profit margin are Vertex Pharmaceuticals (VRTX -1.54%), Nektar Therapeutics (NKTR -2.77%), and Regeneron Pharmaceuticals (REGN -1.73%). But are these highly profitable drug stocks good picks for investors to buy now? 

Check out the latest Regeneron, Nektar, and Vertex earnings call transcripts.

Pill bottle with white pills forming a dollar sign.

Image source: Getty Images.

1. Vertex Pharmaceuticals

Vertex Pharmaceuticals claims a sky-high profit margin of 69%. It's important to note, though, that Vertex only became consistently profitable in 2017. The company lost more than $1.8 billion over the previous five years.

The key to Vertex reaching profitability has been its groundbreaking cystic fibrosis (CF) drugs. Vertex currently has three approved CF drugs -- Kalydeco, Orkambi, and Symdeko. Kalydeco and Orkambi have already achieved blockbuster sales. Symdeko is almost certain to reach the $1 billion sales mark in 2019. 

However, Vertex's profit margin has been boosted tremendously by help from Uncle Sam. Nearly $1.49 billion of the biotech's $2.1 billion in profit last year stemmed from an income tax benefit -- although without this tax benefit, Vertex's profit margin still would have been an impressive 35%.

2. Nektar Therapeutics

Nektar Therapeutics isn't too far behind Vertex, with the biotech's profit margin currently at just under 60%. But there's a major asterisk with the company's profits. Although Nektar ranks as one of the most profitable drugmakers, the company isn't consistently profitable yet.

Nektar's high profit margin is due to a big licensing deal with Bristol-Myers Squibb for immuno-oncology candidate NKTR-214. This deal, which was announced in February 2018, led to Nektar recording an additional $1.06 billion in revenue in the second quarter last year. And that gave the biotech a profit so high that it more than offset losses in the other quarters over the last year.

It might not be too long before Nektar generates nice profits without the help from a big licensing deal. The biotech currently awaits FDA approval for pain drug NKTR-181. Nektar also has four drugs in late-stage clinical studies, including NKTR-214.

3. Regeneron Pharmaceuticals

Regeneron Pharmaceuticals' profit margin tops 36%. Unlike Vertex and Nektar, there aren't any gotchas with Regeneron's tremendous profits. The big biotech really is as profitable as it seems.

One drug is primarily responsible for Regeneron's financial success: Eylea. The company made over $4 billion in sales from the eye-disease drug in the U.S. last year. Its collaboration with Bayer brought in another $1 billion or so for Regeneron in sales outside of the U.S. 

However, Regeneron also has several other approved products that could bolster its profits more in the future. Cholesterol drug Praluent hasn't yet delivered on its potential but could pick up momentum with regulatory approval for the drug in reducing cardiovascular risk. Regeneron and partner Sanofi also market asthma and eczema drug Dupixent and cancer drug Libtayo.

Are they buys?

Regeneron continues to make money hand over fist. However, I'm concerned about the company's reliance on Eylea and the ability for its other products and pipeline candidates to make up for any potential future sales declines for its flagship drug.

Nektar is one of the more promising biotechs on the market. I'm tempted to call the stock as one to buy, but I'd prefer to hold off to see how some of the company's top pipeline candidates fare in late-stage testing.

That leaves Vertex. The company has a strong CF franchise with triple-drug combos likely on the way that could expand its market significantly. Vertex is also hoping to move into other indications outside of CF. I think that Vertex is the best biotech stock on the market and a great pick for investors to buy right now. 

Keith Speights owns shares of Vertex Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$279.07 (-1.54%) $-4.38
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$685.27 (-1.73%) $-12.06
Nektar Therapeutics Stock Quote
Nektar Therapeutics
NKTR
$3.05 (-2.77%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.